Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Acarbose may improve glycemic variability compared to sitagliptin.
Last updated July 12, 2026
Key finding
TBR below target level <3.9 mmol/L was significantly lower in acarbose users (0.45%) compared to sitagliptin users (0.78%), P = 0.042.
This study compared the effects of acarbose and sitagliptin, both added to metformin, on glycemic variability in type 2 diabetes patients.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of acarbose and sitagliptin, both added to metformin, on glycemic variability in type 2 diabetes patients.
Clinical relevance
Understanding the differences in glycemic control between acarbose and sitagliptin can help healthcare providers make informed decisions about diabetes management. Acarbose's ability to reduce time spent in low blood sugar ranges may lead to better overall patient outcomes and fewer complications associated with diabetes.
Keep in mind
The study's sample size and participant demographics may limit generalizability. Potential confounding factors were not accounted for in the analysis. The study did not assess long-term outcomes beyond the intervention period.
Published in
Journal Reference
Publication details and source links for this paper.
Xiaoling C, Suiyuan H, Chu L, et al. Comparison of Acarbose and Sitagliptin Added to Metformin on Glycemic Variability in Type 2 Diabetes. Chinese Medical Journal. 2025;138(9):1116-1125. doi:10.1097/CM9.0000000000003477
Main Effects
Acarbose users had significantly lower TBR <3.9 mmol/L (0.45%) compared to sitagliptin users (0.78%), P = 0.042.
Acarbose users had significantly lower TBR <3.0 mmol/L (0) compared to sitagliptin users (0), P = 0.033.
Acarbose users exhibited a lower CV (22.44 ± 5.08%) compared to sitagliptin users (23.96 ± 5.19%), P <0.001.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Acarbose, Sitagliptin and Coefficient of variation, Time below range, Time in range.
This study contributes evidence to
Primary intervention
Acarbose
Primary outcomes
- Coefficient of variation
- Time below range
- Time in range
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
6
Evidence pairs
192
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and CGM Time in Range
Related evidence
Evidence relationship
DPP-4 Inhibitors and Glucose Variability
Save evidence
Evidence relationship
Alpha-glucosidase inhibitors and CGM Time in Range
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerCoefficient of variation
Sitagliptin → Coefficient of variation
Sitagliptin → Coefficient of variation
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Acarbose reduced TBR <3.9 mmol/L by 0.33% compared to sitagliptin.
- Acarbose users had a CV decrease of 1.52% compared to sitagliptin users.
- No significant difference in TIR was found between the two groups.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients currently using metformin as part of their diabetes management.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The findings are based on short-term outcomes and may not reflect long-term efficacy.
- Further research is needed to explore the mechanisms behind the observed differences.
Between the Lines
- The study's sample size and participant demographics may limit generalizability.
- Potential confounding factors were not accounted for in the analysis.
- The study did not assess long-term outcomes beyond the intervention period.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Alpha-glucosidase inhibitors and Glucose Variability, Alpha-glucosidase inhibitors and CGM Time in Range.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Alpha-glucosidase inhibitors Evidence Hub
All studies on Alpha-glucosidase inhibitors
2 studies
intervention_hubContributes to Alpha-glucosidase inhibitors evidence base.
CGM Time in Range Evidence Hub
All studies measuring CGM Time in Range
2 studies
outcome_hubMeasures CGM Time in Range as a key outcome.
Glucose Variability Evidence Hub
All studies measuring Glucose Variability
2 studies
outcome_hubMeasures Glucose Variability as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Acarbose and Coefficient of variation
Intervention: AcarboseOutcome: Coefficient of variation
2 results
All studies on Acarbose and Time below range
Intervention: AcarboseOutcome: Time below range
2 results
All studies on Acarbose
Intervention: Acarbose
2 results
All studies measuring Coefficient of variation
Outcome: Coefficient of variation
2 results
All studies measuring Time below range
Outcome: Time below range
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve cgm time in range?
Strong Evidence
DPP-4 Inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
- 2
Time below range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve glucose variability?
Strong Evidence
DPP-4 Inhibitors may improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Coefficient of variation
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve cgm time in range?
Strong Evidence
Alpha-glucosidase inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
- 2
Time below range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve glucose variability?
Strong Evidence
Alpha-glucosidase inhibitors may improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Coefficient of variation
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Carnosine shows little effect on cardiovascular outcomes in diabetesSitagliptin improves kidney function in type 1 diabetesGlucose variability increases with age in type 2 diabetes patientsNutritional Therapy and AGIs Improve Postprandial Glucose in DiabetesTelemedicine improves glucose control in nursing home residents with diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.